Corporate ActionJul 2, 2026, 04:14 PM
Pulsenmore Registers 3.125M Shares for Resale After Private Placement
AI Summary
Pulsenmore Ltd. filed an F-1 registration statement to register 3,125,000 ordinary shares for resale by a selling shareholder. These shares are issuable upon the exercise of pre-funded and ordinary warrants from a private placement on June 26, 2026, which generated approximately $7.5 million in gross proceeds for the company. While Pulsenmore will not receive proceeds from the resale, it may receive up to $7.5 million if the warrants are exercised for cash. The company, an emerging medical device firm, highlighted recent FDA approval for its Pulsenmore ES device and ongoing expansion into new geographic markets.
Key Highlights
- Registers 3,125,000 ordinary shares for resale by selling shareholder.
- Includes 1,562,500 shares from pre-funded warrants and 1,562,500 from ordinary warrants.
- Private placement on June 26, 2026, raised $7.5 million gross proceeds.
- Pulsenmore ES received FDA approval in October 2025.
- Pulsenmore ES sales in Israel reached NIS 9.1 million (approx. $2.9 million) in 2025.
- Company holds over 21 families of patents and applications.
- 6,502,844 ordinary shares outstanding as of July 1, 2026.
- Cash and equivalents were NIS 21,604 thousand (approx. $13,256 thousand) as of Dec 31, 2025.
Price Impact
More from PLSM